MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
+Added: Market Information
+Added: Our common stock is quoted on the New York Stock Exchange under the symbol “HAE”.
+Added: As of April 2, 2022, we had 108 stockholders of record.
+Added: We have not historically paid cash dividends.
Issuer Purchases of Equity Securities
In May 2019, our Board of Directors authorized the repurchase of up to $500 million of Haemonetics common shares over the two year period ending May 2021.
−Removed: We had no share repurchases during fiscal 2021.
−Removed: The total remaining authorization for repurchases of our common stock under the share repurchase program was $325 million as of April 3, 2021.
−Removed: We did not make any additional share repurchases under this program which expired in May 2021.
−Removed: SELECTED FINANCIAL DATA
−Removed: This item is no longer required as we have elected to early adopt the changes to Item 301 of Regulation S-K contained in the Securities and Exchange Commission's Release No.
+Added: During fiscal 2022, we did not make any additional repurchases under this program, which expired in May 2021.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.